Sensitization to the prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA).
Neuropharmacology June 2019 Daniel W Curry, Laís F Berro, Andie R Belkoff et al.
The recreational drug 3,4-methylenedioxymethamphetamine (MDMA) has well documented prosocial effects and is currently under clinical investigation as a treatment for patients with PTSD, autism, and other conditions. Early clinical trials have found that MDMA-assisted therapy may have robust long-lasting therapeutic effects, yet the mechanism by which acute treatments produce these long-term...